Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Prelude Therapeutics IncPRLD · Entity 5561 | Chief Scientific Officer | February 04, 2026 | February 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Prelude Therapeutics Inc
Report date February 04, 2026 · Filed February 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2036-02-03 | Direct | 230,000 |
Reported balance
After 2026-02-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-04 · Grant · Acquired 230,000 · Balance 230,000 F1: The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 04, 2026 Filed Feb 5, 2026 21:12 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 230,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001824632-26-000002 · primarydocument.xml · derivative · entry 1 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2036-02-03 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 21:32 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001562180-25-000958 · primarydocument.xml · derivative · entry 1 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2035-02-04 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on Feb 4, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 23:07 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001562180-24-002137 · primarydocument.xml · derivative · entry 1 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-02-28 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on March 1, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 21:08 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 135,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-23-001170 · primarydocument.xml · derivative · entry 1 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2033-02-06 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 7, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 00:12 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $10.58 | $0.00 |
DisclosureSEC source: 0001209191-22-011038 · doc4.xml · derivative · entry 1 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 15, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| August 27, 2021 Filed Aug 30, 2021 21:16 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,014 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001209191-21-053867 · doc4.xml · derivative · entry 8 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,018 Underlying: Common Stock · 6,014 shares Expires 2028-11-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| August 27, 2021 Filed Aug 30, 2021 21:16 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 607 | $37.08 | $22,505.19 |
DisclosureSEC source: 0001209191-21-053867 · doc4.xml · nonDerivative · entry 6 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,920 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| August 27, 2021 Filed Aug 30, 2021 21:16 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 2,707 | $36.23 | $98,085.44 |
DisclosureSEC source: 0001209191-21-053867 · doc4.xml · nonDerivative · entry 5 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,527 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| August 27, 2021 Filed Aug 30, 2021 21:16 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 2,700 | $35.32 | $95,376.69 |
DisclosureSEC source: 0001209191-21-053867 · doc4.xml · nonDerivative · entry 4 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,234 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| August 27, 2021 Filed Aug 30, 2021 21:16 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionCommon Stock | 6,014 | $1.43 | $8,600.02 |
DisclosureSEC source: 0001209191-21-053867 · doc4.xml · nonDerivative · entry 3 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 21:16 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,700 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001209191-21-053867 · doc4.xml · derivative · entry 7 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,032 Underlying: Common Stock · 1,700 shares Expires 2028-11-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 21:16 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 1,700 | $35.19 | $59,819.43 |
DisclosureSEC source: 0001209191-21-053867 · doc4.xml · nonDerivative · entry 2 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,920 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 21:16 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionCommon Stock | 1,700 | $1.43 | $2,431.00 |
DisclosureSEC source: 0001209191-21-053867 · doc4.xml · nonDerivative · entry 1 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 20:44 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,728 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001209191-21-051885 · doc4.xml · derivative · entry 5 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,732 Underlying: Common Stock · 1,728 shares Expires 2028-11-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 20:44 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 558 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-21-051885 · doc4.xml · derivative · entry 4 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,672 Underlying: Common Stock · 558 shares Expires 2030-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly beginning on March 6, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 20:44 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 2,286 | $35.07 | $80,161.33 |
DisclosureSEC source: 0001209191-21-051885 · doc4.xml · nonDerivative · entry 3 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,920 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 20:44 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionCommon Stock | 1,728 | $1.43 | $2,471.04 |
DisclosureSEC source: 0001209191-21-051885 · doc4.xml · nonDerivative · entry 2 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 20:44 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionCommon Stock | 558 | $1.89 | $1,054.62 |
DisclosureSEC source: 0001209191-21-051885 · doc4.xml · nonDerivative · entry 1 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 23:27 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001209191-21-048688 · doc4.xml · derivative · entry 4 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,460 Underlying: Common Stock · 20,000 shares Expires 2028-11-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 23:27 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 680 | $36.09 | $24,539.98 |
DisclosureSEC source: 0001209191-21-048688 · doc4.xml · nonDerivative · entry 3 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,920 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 23:27 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 19,320 | $35.45 | $684,839.90 |
DisclosureSEC source: 0001209191-21-048688 · doc4.xml · nonDerivative · entry 2 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,600 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 23:27 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionCommon Stock | 20,000 | $1.43 | $28,600.00 |
DisclosureSEC source: 0001209191-21-048688 · doc4.xml · nonDerivative · entry 1 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| July 20, 2021 Filed Jul 22, 2021 22:17 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (Right to Buy) · Derivative | 95,000 | $0.00 Strike: $31.23 | $0.00 |
DisclosureSEC source: 0001209191-21-047847 · doc4.xml · derivative · entry 1 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2031-07-19 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on July 20, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 07, 2021 Filed May 11, 2021 22:46 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001209191-21-031847 · doc4.xml · derivative · entry 5 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,460 Underlying: Common Stock · 10,000 shares Expires 2028-11-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| May 07, 2021 Filed May 11, 2021 22:46 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 200 | $41.85 | $8,370.00 |
DisclosureSEC source: 0001209191-21-031847 · doc4.xml · nonDerivative · entry 4 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,920 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| May 07, 2021 Filed May 11, 2021 22:46 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 5,836 | $41.14 | $240,090.12 |
DisclosureSEC source: 0001209191-21-031847 · doc4.xml · nonDerivative · entry 3 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,120 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.67 to $41.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| May 07, 2021 Filed May 11, 2021 22:46 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 3,964 | $40.30 | $159,732.15 |
DisclosureSEC source: 0001209191-21-031847 · doc4.xml · nonDerivative · entry 2 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,956 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.64 to $40.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| May 07, 2021 Filed May 11, 2021 22:46 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionCommon Stock | 10,000 | $1.43 | $14,300.00 |
DisclosureSEC source: 0001209191-21-031847 · doc4.xml · nonDerivative · entry 1 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| April 08, 2021 Filed Apr 15, 2021 23:14 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,630 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001209191-21-026875 · doc4.xml · derivative · entry 6 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,460 Underlying: Common Stock · 4,630 shares Expires 2028-11-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| April 08, 2021 Filed Apr 15, 2021 23:14 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 1,669 | $39.57 | $66,040.33 |
DisclosureSEC source: 0001209191-21-026875 · doc4.xml · nonDerivative · entry 5 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,920 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.39 to $40.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| April 08, 2021 Filed Apr 15, 2021 23:14 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 669 | $38.97 | $26,072.67 |
DisclosureSEC source: 0001209191-21-026875 · doc4.xml · nonDerivative · entry 4 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,589 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.38 to $39.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| April 08, 2021 Filed Apr 15, 2021 23:14 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 875 | $37.72 | $33,003.43 |
DisclosureSEC source: 0001209191-21-026875 · doc4.xml · nonDerivative · entry 3 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,258 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.38 to $38.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| April 08, 2021 Filed Apr 15, 2021 23:14 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 1,417 | $36.97 | $52,387.48 |
DisclosureSEC source: 0001209191-21-026875 · doc4.xml · nonDerivative · entry 2 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,133 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.37 to $37.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| April 08, 2021 Filed Apr 15, 2021 23:14 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantCommon Stock | 4,630 | $1.43 | $6,620.90 |
DisclosureSEC source: 0001209191-21-026875 · doc4.xml · nonDerivative · entry 1 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,550 F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 21:55 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,370 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001209191-21-026294 · doc4.xml · derivative · entry 5 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,090 Underlying: Common Stock · 15,370 shares Expires 2028-11-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 21:55 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 200 | $40.30 | $8,060.00 |
DisclosureSEC source: 0001209191-21-026294 · doc4.xml · nonDerivative · entry 4 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,920 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 21:55 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 6,881 | $39.63 | $272,678.89 |
DisclosureSEC source: 0001209191-21-026294 · doc4.xml · nonDerivative · entry 3 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,120 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.26 to $40.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 21:55 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 8,289 | $39.02 | $323,405.28 |
DisclosureSEC source: 0001209191-21-026294 · doc4.xml · nonDerivative · entry 2 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,001 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.26 to $39.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 21:55 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantCommon Stock | 15,370 | $1.43 | $21,979.10 |
DisclosureSEC source: 0001209191-21-026294 · doc4.xml · nonDerivative · entry 1 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,290 F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.